INAB vs CRSP vs EDIT vs FATE

For growth investors, Editas Medicine, Inc.

(EDIT) is the stronger pick with 25. 4% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Analysts rate CRISPR Therapeutics AG (CRSP) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CRISPR Therapeutics AG (CRSP) delivered a total return of -58.

0%, compared to -99. 5% for IN8bio, Inc. (INAB). Over 10 years, the gap is even starker: CRSP returned +269. 2% versus INAB's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IN8bio, Inc.

(INAB) is the lower-risk stock at 1. 89β versus Editas Medicine, Inc. 's 2. 52β — meaning EDIT is approximately 34% more volatile than INAB relative to the S&P 500. On balance sheet safety, IN8bio, Inc. (INAB) carries a lower debt/equity ratio of 10% versus 3% for Editas Medicine, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Editas Medicine, Inc.

(EDIT) is pulling ahead at 25. 4% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Editas Medicine, Inc. grew EPS 37. 5% year-over-year, compared to -678. 9% for IN8bio, Inc.. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IN8bio, Inc.

(INAB) is the more profitable company, earning 0. 0% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INAB leads at 0. 0% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — EDIT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, CRISPR Therapeutics AG (CRSP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+269.

2% 10Y return). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRSP: +269. 2%, EDIT: -92. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INAB is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock; EDIT is a small-cap high-growth stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.